Trifecta Capital Advisors, LLC Bristol Myers Squibb CO Transaction History
Trifecta Capital Advisors, LLC
- $658 Billion
- Q3 2025
A detailed history of Trifecta Capital Advisors, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Trifecta Capital Advisors, LLC holds 38 shares of BMY stock, worth $1,778. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38
Previous 538
92.94%
Holding current value
$1,778
Previous $24.9 Million
93.12%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding BMY
# of Institutions
2,680Shares Held
1.58BCall Options Held
28MPut Options Held
28.4M-
Vanguard Group Inc Valley Forge, PA196MShares$9.17 Billion0.14% of portfolio
-
Black Rock Inc. New York, NY159MShares$7.43 Billion0.15% of portfolio
-
State Street Corp Boston, MA96.6MShares$4.52 Billion0.16% of portfolio
-
Jpmorgan Chase & CO New York, NY86.2MShares$4.03 Billion0.26% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA73MShares$3.42 Billion0.55% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $99.5B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...